DK1848415T3 - Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose - Google Patents
Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel skleroseInfo
- Publication number
- DK1848415T3 DK1848415T3 DK06720863.7T DK06720863T DK1848415T3 DK 1848415 T3 DK1848415 T3 DK 1848415T3 DK 06720863 T DK06720863 T DK 06720863T DK 1848415 T3 DK1848415 T3 DK 1848415T3
- Authority
- DK
- Denmark
- Prior art keywords
- rasagiline
- treatment
- multiple sclerosis
- combination therapy
- glatiramer acetate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65401205P | 2005-02-17 | 2005-02-17 | |
PCT/US2006/005741 WO2006089164A1 (en) | 2005-02-17 | 2006-02-17 | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1848415T3 true DK1848415T3 (da) | 2013-07-08 |
Family
ID=36916800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06720863.7T DK1848415T3 (da) | 2005-02-17 | 2006-02-17 | Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080261894A1 (da) |
EP (1) | EP1848415B1 (da) |
CA (1) | CA2596664A1 (da) |
DK (1) | DK1848415T3 (da) |
ES (1) | ES2420404T3 (da) |
HR (1) | HRP20130622T1 (da) |
IL (1) | IL184037A0 (da) |
PL (1) | PL1848415T3 (da) |
PT (1) | PT1848415E (da) |
RS (1) | RS52867B (da) |
SI (1) | SI1848415T1 (da) |
WO (1) | WO2006089164A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
EP2298277A1 (en) * | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記 |
MX2015007678A (es) * | 2012-12-21 | 2015-09-07 | Teva Pharma | Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
US4529811A (en) * | 1981-03-02 | 1985-07-16 | G. D. Searle & Co. | Process for isolating organic compounds and lithium salt complexes useful in said process |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
US5767164A (en) * | 1991-04-04 | 1998-06-16 | Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5444095A (en) * | 1991-04-04 | 1995-08-22 | University Of Toronto, Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
DE69738275T2 (de) * | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
CA2337688C (en) * | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
US20040013643A1 (en) * | 2000-09-19 | 2004-01-22 | Novlmmune S.A. | Methods for treatment of multiple sclerosis with statins |
WO2003048735A2 (en) * | 2001-12-04 | 2003-06-12 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
SI2336184T1 (sl) * | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Dajanje sredstev za zdravljenje vnetij |
UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
WO2004045515A2 (en) * | 2002-11-15 | 2004-06-03 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
WO2005011605A2 (en) * | 2003-08-01 | 2005-02-10 | Medarex, Inc. | Combination therapies for multiple sclerosis |
AU2005269416B2 (en) * | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
CA2579656C (en) * | 2004-09-09 | 2014-11-04 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
UA93669C2 (ru) * | 2005-02-02 | 2011-03-10 | Тева Фармасьютикл Индастриз, Лтд. | Способ приготовления полипептидной смеси c использованием гидрогенолиза |
BRPI0608209A2 (pt) * | 2005-02-23 | 2010-11-09 | Teva Pharma | mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida |
CA2606194A1 (en) * | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
JP5769923B2 (ja) * | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
NZ577460A (en) * | 2006-12-14 | 2012-01-12 | Teva Pharma | Crystalline solid rasagiline base |
NZ577623A (en) * | 2006-12-14 | 2011-05-27 | Teva Pharma | Tannate salt of rasagiline |
JP2011504925A (ja) * | 2007-11-28 | 2011-02-17 | テバ ファーマシューティカル インダストリーズ リミティド | 臨床的に確実な多発性硬化症の発症を遅延させる方法 |
-
2006
- 2006-02-17 CA CA002596664A patent/CA2596664A1/en not_active Abandoned
- 2006-02-17 PT PT67208637T patent/PT1848415E/pt unknown
- 2006-02-17 EP EP06720863A patent/EP1848415B1/en active Active
- 2006-02-17 ES ES06720863T patent/ES2420404T3/es active Active
- 2006-02-17 PL PL06720863T patent/PL1848415T3/pl unknown
- 2006-02-17 RS RS20130264A patent/RS52867B/en unknown
- 2006-02-17 DK DK06720863.7T patent/DK1848415T3/da active
- 2006-02-17 US US11/884,633 patent/US20080261894A1/en not_active Abandoned
- 2006-02-17 SI SI200631607T patent/SI1848415T1/sl unknown
- 2006-02-17 WO PCT/US2006/005741 patent/WO2006089164A1/en active Application Filing
-
2007
- 2007-06-19 IL IL184037A patent/IL184037A0/en unknown
-
2013
- 2013-07-02 HR HRP20130622TT patent/HRP20130622T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ES2420404T3 (es) | 2013-08-23 |
CA2596664A1 (en) | 2006-08-24 |
EP1848415A4 (en) | 2010-05-26 |
EP1848415A1 (en) | 2007-10-31 |
US20080261894A1 (en) | 2008-10-23 |
EP1848415B1 (en) | 2013-04-03 |
SI1848415T1 (sl) | 2013-08-30 |
PT1848415E (pt) | 2013-06-27 |
IL184037A0 (en) | 2008-12-29 |
WO2006089164A1 (en) | 2006-08-24 |
PL1848415T3 (pl) | 2013-10-31 |
RS52867B (en) | 2013-12-31 |
HRP20130622T1 (en) | 2013-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1848415T3 (da) | Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose | |
DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
DK1638589T3 (da) | Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose | |
IL180992A0 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
DK1951866T3 (da) | Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer | |
IL186194A0 (en) | Markers associated with the therapeutic efficacy of glatiramer acetate | |
DK1773361T4 (da) | Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme | |
DK1889065T3 (da) | Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent | |
DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
DK2137537T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
DK2139517T3 (da) | Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme | |
DK1765391T3 (da) | Bakterielle præparater til behandlingen af cancer | |
EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
DK2063881T3 (da) | Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer | |
DK1896077T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme | |
PL2818145T3 (pl) | Nowy system uciskowy do leczenia i zapobiegania patologiom pochodzenia żylnego | |
DK1919290T3 (da) | Fremgangsmåder og produkter til behandling af sygdomme | |
DK1709082T3 (da) | Sammensætning til behandling af patologi knyttet til MSRV/HERV-W | |
DK3332789T3 (da) | Cladribinkur til behandling af multipel sklerose | |
EP1805210A4 (en) | NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | |
DK1670482T4 (da) | Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme | |
DK1812797T3 (da) | Sammensætninger og fremgangsmåder til behandling og forebyggelse af hyperproliferative sygdomme | |
ITRM20050478A1 (it) | Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia. |